ATRS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Stats
今日成交量	1.76M
平均成交量	5.23M
市值	0.00
EPS	$-0.0100 ( 2022-05-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	14.95
ATR14	$0.104 (1.86%)

Insider Trading

Date	Person	Action	Amount	type
2022-05-24	Gueth Anton	Sell	79 645	Common Stock
2022-05-24	Gueth Anton	Sell	61 930	Stock Option (right to buy)
2022-05-24	Gueth Anton	Sell	99 395	Stock Option (right to buy)
2022-05-24	Gueth Anton	Sell	150 000	Stock Option (right to buy)
2022-05-24	Gueth Anton	Sell	80 318	Stock Option (right to buy)

INSIDER POWER
-100.00
Last 97 transactions
Buy: 1 667 582 \| Sell: 3 999 780

音量相关性

長: 0.33 (neutral)

短: 0.37 (neutral)

Signal:(78.671) Neutral

Antares Pharma Inc 相关性

10 最正相关
SJ	0.968
SERA	0.963
THCPU	0.962
SEAC	0.958
PEGA	0.954
HSKA	0.951
MLTX	0.951
GXII	0.948
KIN	0.947
ISRG	0.946

10 最负相关
CHDN	-0.971
CFBK	-0.968
HURC	-0.965
PEAR	-0.951
AGIL	-0.951
GRNA	-0.95
VRAY	-0.948
PROC	-0.947
SNGX	-0.946
VWE	-0.942

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Antares Pharma Inc 相关性 - 货币/商品

0.03
( neutral )

0.71
( moderate )

0.00
( neutral )

0.43
( neutral )

-0.38
( neutral )

-0.03
( neutral )

Antares Pharma Inc 财务报表

Annual	2021
营收:	$183.98M
毛利润:	$115.70M (62.89 %)
EPS:	$0.280

FY	2021
营收:	$183.98M
毛利润:	$115.70M (62.89 %)
EPS:	$0.280

FY	2020
营收:	$149.60M
毛利润:	$86.50M (57.82 %)
EPS:	$0.340

FY	2019
营收:	$123.86M
毛利润:	$73.39M (59.25 %)
EPS:	$-0.0100

Financial Reports:

No articles found.

Antares Pharma Inc

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.